Loading
A single-centre trial at Tata Memorial found that adding nivolumab at about a twentieth of the usual dose to chemotherapy improved outcomes in head and neck cancer. Confirmatory trials against standard-dose immunotherapy are needed before low-dose labels could make immunotherapy affordable for millions.
Randomised confirmatory trials of low-dose PD-1 blockade (e.g., nivolumab 20 mg every three weeks, as tested at Tata Memorial in head and neck cancer with an OS benefit versus chemotherapy alone) in additional indications and against standard-dose immunotherapy, with PK and receptor-occupancy sub-studies, and a regulatory pathway for low-dose labels or guideline recommendations in resource-limited settings. Uncertainty is substantial: the evidence base is a single-centre trial and non-inferiority to full dose has not been shown.
Shares Vijay Patil, Kumar Prabhash, Tata Memorial Centre, Wrong doses.
Shares Vijay Patil, Kumar Prabhash, Tata Memorial Centre, Wrong doses.
Shares CheckMate 227, KEYNOTE-042, Wrong doses, Prices and value.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care, Nivolumab.
Shares Vijay Patil, Kumar Prabhash, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
Shares CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy, Wrong doses, Prices and value, Nivolumab.
Shares CheckMate 227, KEYNOTE-042, Prices and value, Nivolumab.
Shares CheckMate 227, KEYNOTE-024 & KEYNOTE-189, Nivolumab, PD-1.